Overview

Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, blinded, parallel group, placebo-controlled trial on 32 evaluable healthy male and non-pregnant female, 18-50 year old volunteers. The investigators goal is to observe the pharmacokinetics of fenobam after oral administration of 50, 100 or 150 mg in groups of healthy individuals and to compare the side effects and tolerability of a single dose of fenobam with placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Imidazole